Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 123,268 shares, an increase of 511.1% from the February 12th total of 20,170 shares. Based on an average daily volume of 653,011 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 653,011 shares, the short-interest ratio is presently 0.2 days.

Daiichi Sankyo Stock Down 1.5%

DSNKY stock opened at $18.00 on Thursday. Daiichi Sankyo has a 52 week low of $17.44 and a 52 week high of $28.21. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The firm has a 50-day simple moving average of $19.76 and a 200-day simple moving average of $22.35. The stock has a market capitalization of $34.10 billion, a P/E ratio of 16.51, a P/E/G ratio of 1.10 and a beta of -0.35.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.05. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%.The company had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.88 billion. Equities analysts forecast that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.